Two decades covering equity markets. Writes on single stocks, sectors, valuations and the trades behind the tape.

Ahead of Medtronic's fiscal Q1 earnings, Needham predicts a beat and a higher fiscal 2027 outlook. Newer products like Affera PFA, Symplicit

Anthropic may go public as soon as late September or early October. The AI firm could let some existing shareholders sell stock in the IPO,

Alcohol and cigarette use are at historic lows, but consumer cravings haven't disappeared—they've shifted. From energy drinks to legal canna

The Trump administration's plan for an AI self-regulator is stuck awaiting senior buy-in, even as officials consider broad semiconductor tar

Aurora Spine's Q2 revenue slipped to $3.7 million, deepening its loss and sending shares down 17%. The company cited a softer pain market an

UBS raised its price target on Abercrombie & Fitch to $185 from $153, saying the retailer's growth story has staying power. The bank points

The US Treasury's attempt to lower borrowing costs failed, but bitcoin, gold, and silver rallied sharply. Here's what it means for investors

Nvidia's blowout quarter and bold outlook, plus upbeat forecasts from Salesforce and CrowdStrike, lifted US stocks on Thursday. The AI boom

Oppenheimer lifted its price target on Braze to $36, expecting $220 million in fiscal Q2 revenue as AI-powered marketing tools see solid dem

RBC Capital Markets lifted its price target on Nutanix to $90 after a strong fiscal Q4. The firm points to faster growth in external storage

Latin American stocks and currencies slipped as markets digested sticky US inflation and awaited Kevin Warsh's first Jackson Hole speech. Ar

Truworths International posted a 2.6% fall in full-year profit and trimmed its final dividend as cautious shoppers in South Africa and the U